Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03117738 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease
A Phase 1 study, sponsored by Nature Cell Co..
- Completed
- Registry status
- Phase 1
- Development phase
- 21
- Enrollment target
NCT03117738: Completed Phase 1 study, sponsored by Nature Cell Co..
NCT03117738 is a Phase 1 study that has completed, run by Nature Cell Co.. The registered enrollment target is 21 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03117738, a Phase 1 study, has completed, sponsored by Nature Cell Co..
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo control will be administered via I.V. at Week 0. This procedure will be repeated 9 times at 2-week interval. Subjects will be scheduled for two follow-up visits at Weeks 30 and 52 to evaluate primary and secondary outcome endpoints.
Primary Outcome
Number of subjects with treatment related adverse events as assessed by analysis of adverse events including symptoms, and abnormal findings on physical examination, vital signs, ECG, and standard laboratory examination results
Interventions
- DRUG AstroStem
- OTHER Placebo-Control
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2017-05-09 |
| Est. Completion | 2019-08-31 |
| Phase | Phase 1 |
What the finished NCT03117738 record still lists
NCT03117738 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (65% lower).
The record links to 0 conditions, and to 2 interventions - of which AstroStem is the first listed.
NCT03117738 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03117738 about?
NCT03117738 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease". This is a randomized, double-blind, placebo-controlled, parallel-group comparison study in subjects with Alzheimer's Disease. Following first screening period, subjects will be randomly assigned into one of the following arms: AstroStem and placebo control in a 1:1 ratio. AstroStem or placebo contro...
What is the current status of trial NCT03117738?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 21 participants. The study started on 2017-05-09. Estimated completion is 2019-08-31.
What interventions are being tested in trial NCT03117738?
The interventions under investigation include: AstroStem (DRUG), Placebo-Control (OTHER).
Who is sponsoring clinical trial NCT03117738?
This trial is sponsored by Nature Cell Co., which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03117738's enrollment target sits among peer trials
21 1615th of 2000 higher than 372 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI